CLINICAL TRIALS PROFILE FOR RIMANTADINE HYDROCHLORIDE

505(b)(2) Clinical Trials for Rimantadine Hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT01413490 ↗	Hepatitis C Rimantadine and Antiviral Combination Therapy	Completed	Cancer Research UK		2012-05-01	Hepatitis C virus is one of the leading causes of liver failure and liver cancer worldwide. Current treatment of hepatitis C infection is only successful in about half of those who are eligible. The current treatment aims to boost the host immune system but does not directly act on the virus. Many drugs are in various stages of development that target the virus directly - their specific mode of action is confirmed by showing the virus is forced to adapt in the presence of the drug. As with many viruses, treating with only one specific drug would quickly lead to the virus adapting and becoming resistant. We therefore need to find new combinations of directly acting drugs. Rimantadine has already been shown in the laboratory to target hepatitis C directly. We have designed this study to see if it happens in real life as well. If so, we could use rimantadine to help fight hepatitis c more effectively.
New Combination	NCT01413490 ↗	Hepatitis C Rimantadine and Antiviral Combination Therapy	Completed	The Leeds Teaching Hospitals NHS Trust		2012-05-01	Hepatitis C virus is one of the leading causes of liver failure and liver cancer worldwide. Current treatment of hepatitis C infection is only successful in about half of those who are eligible. The current treatment aims to boost the host immune system but does not directly act on the virus. Many drugs are in various stages of development that target the virus directly - their specific mode of action is confirmed by showing the virus is forced to adapt in the presence of the drug. As with many viruses, treating with only one specific drug would quickly lead to the virus adapting and becoming resistant. We therefore need to find new combinations of directly acting drugs. Rimantadine has already been shown in the laboratory to target hepatitis C directly. We have designed this study to see if it happens in real life as well. If so, we could use rimantadine to help fight hepatitis c more effectively.

All Clinical Trials for Rimantadine Hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00298233 ↗	High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza	Completed	University of Oxford	Phase 2	2006-02-01	Influenza, also known as the flu, is a contagious respiratory illness caused by influenza viruses. The illness can range in severity, from mild to severe to even death, and it causes an estimated 500,000 to 1,000,000 deaths worldwide each year. In the last several years, there have been increasing numbers of human cases of avian influenza, or bird flu. This trend may pose a threat of a future pandemic--worldwide outbreak of disease--with an avian influenza virus that can easily spread from person to person. Oseltamivir is an antiviral medication that is used to treat people with uncomplicated human influenza, and it may be effective in treating people with either severe human influenza or avian influenza. The purpose of this international study is to compare standard-dose oseltamivir versus high-dose oseltamivir for treating people who are hospitalized with severe human influenza or avian influenza.
NCT00298233 ↗	High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza	Completed	Wellcome Trust	Phase 2	2006-02-01	Influenza, also known as the flu, is a contagious respiratory illness caused by influenza viruses. The illness can range in severity, from mild to severe to even death, and it causes an estimated 500,000 to 1,000,000 deaths worldwide each year. In the last several years, there have been increasing numbers of human cases of avian influenza, or bird flu. This trend may pose a threat of a future pandemic--worldwide outbreak of disease--with an avian influenza virus that can easily spread from person to person. Oseltamivir is an antiviral medication that is used to treat people with uncomplicated human influenza, and it may be effective in treating people with either severe human influenza or avian influenza. The purpose of this international study is to compare standard-dose oseltamivir versus high-dose oseltamivir for treating people who are hospitalized with severe human influenza or avian influenza.
NCT00298233 ↗	High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza	Completed	World Health Organization	Phase 2	2006-02-01	Influenza, also known as the flu, is a contagious respiratory illness caused by influenza viruses. The illness can range in severity, from mild to severe to even death, and it causes an estimated 500,000 to 1,000,000 deaths worldwide each year. In the last several years, there have been increasing numbers of human cases of avian influenza, or bird flu. This trend may pose a threat of a future pandemic--worldwide outbreak of disease--with an avian influenza virus that can easily spread from person to person. Oseltamivir is an antiviral medication that is used to treat people with uncomplicated human influenza, and it may be effective in treating people with either severe human influenza or avian influenza. The purpose of this international study is to compare standard-dose oseltamivir versus high-dose oseltamivir for treating people who are hospitalized with severe human influenza or avian influenza.
NCT00298233 ↗	High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	2006-02-01	Influenza, also known as the flu, is a contagious respiratory illness caused by influenza viruses. The illness can range in severity, from mild to severe to even death, and it causes an estimated 500,000 to 1,000,000 deaths worldwide each year. In the last several years, there have been increasing numbers of human cases of avian influenza, or bird flu. This trend may pose a threat of a future pandemic--worldwide outbreak of disease--with an avian influenza virus that can easily spread from person to person. Oseltamivir is an antiviral medication that is used to treat people with uncomplicated human influenza, and it may be effective in treating people with either severe human influenza or avian influenza. The purpose of this international study is to compare standard-dose oseltamivir versus high-dose oseltamivir for treating people who are hospitalized with severe human influenza or avian influenza.
NCT00979667 ↗	A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection	Terminated	Food and Health Bureau, Hong Kong	Phase 3	2009-10-01	To evaluate the efficacy of oseltamivir ,as compared with the placebo arm and zanamivir with its control arm with respect to symptoms duration among patients infected with influenza A (H1N1) virus.
NCT00979667 ↗	A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection	Terminated	Hospital Authority	Phase 3	2009-10-01	To evaluate the efficacy of oseltamivir ,as compared with the placebo arm and zanamivir with its control arm with respect to symptoms duration among patients infected with influenza A (H1N1) virus.
NCT00979667 ↗	A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection	Terminated	Chinese University of Hong Kong	Phase 3	2009-10-01	To evaluate the efficacy of oseltamivir ,as compared with the placebo arm and zanamivir with its control arm with respect to symptoms duration among patients infected with influenza A (H1N1) virus.

Clinical Trial Conditions for Rimantadine Hydrochloride

Condition Name

Condition Name for Rimantadine Hydrochloride
Intervention	Trials
Influenza	3
Influenza, Human	1
Severe Influenza	1
Upper Respiratory Tract Infection	1

Condition MeSH

Condition MeSH for Rimantadine Hydrochloride
Intervention	Trials
Influenza, Human	4
Respiratory Tract Infections	2
Infections	2
Infection	2

Clinical Trial Locations for Rimantadine Hydrochloride

Trials by Country

Trials by Country for Rimantadine Hydrochloride
Location	Trials
United States	21
Thailand	4
Argentina	2
China	1
United Kingdom	1

Trials by US State

Trials by US State for Rimantadine Hydrochloride
Location	Trials
Michigan	1
Massachusetts	1
Maryland	1
Louisiana	1
Kentucky	1

Clinical Trial Progress for Rimantadine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Rimantadine Hydrochloride
Clinical Trial Phase	Trials
Phase 3	1
Phase 2/Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for Rimantadine Hydrochloride
Clinical Trial Phase	Trials
Completed	4
Withdrawn	1
Terminated	1

Clinical Trial Sponsors for Rimantadine Hydrochloride

Sponsor Name

Sponsor Name for Rimantadine Hydrochloride
Sponsor	Trials
University of Oxford	2
National Institute of Allergy and Infectious Diseases (NIAID)	2
Hoffmann-La Roche	1

Sponsor Type

Sponsor Type for Rimantadine Hydrochloride
Sponsor	Trials
Other	9
NIH	2
Industry	1

Rimantadine Hydrochloride Market Analysis and Financial Projection

Last updated: April 25, 2026

Rimantadine Hydrochloride: Clinical Trial Update, Market Analysis, and Projection

What does the latest clinical-trial landscape show for rimantadine hydrochloride?

Rimantadine hydrochloride is an antiviral that historically targets influenza A. Clinical development activity has largely shifted from late-stage “new drug” programs to (1) older-generation evidence consolidation and (2) formulation or non-interventional evidence work. A current, active late-stage pipeline for new rimantadine drug product approvals is not reflected in recent public trial registries at the scale seen for modern influenza agents.

Observed trial signal (public registries):

• Searchable contemporary activity typically concentrates in older studies or non-primary interventional follow-ons rather than large Phase 3 registrational trials.
• The core clinical narrative for rimantadine is anchored in influenza A efficacy and resistance dynamics and in comparative use vs other influenza antivirals in seasons where drug selection depends on resistance patterns.

Clinical implications for decision-makers:

• Rimantadine’s commercial viability has historically been constrained by influenza A resistance (notably to adamantanes) and by changes in standard-of-care selection as neuraminidase inhibitors and, more recently, polymerase inhibitors and other classes gained adoption.
• For any new sponsor, the bottleneck is not “whether influenza antivirals work,” but whether rimantadine can produce a credible dose-exposure-efficacy and resistance-relevant dataset against current guidelines and circulating strain susceptibility.

Practical read-through for 2025-2026 business planning:

• Rimantadine is more consistent with short-cycle, seasonal procurement strategies than with long-cycle, capital-intensive global development.
• The highest-value market segments remain geographies or institutional buyers where rimantadine is stocked, included in national formularies, or where procurement cycles continue to rely on older antiviral options.

Source anchor for clinical positioning and historical use: Rimantadine is an anti-influenza agent in the adamantane class with activity against influenza A. The product identity and pharmacologic class are reflected across drug monographs and regulatory listings. (See cited sources [1]-[4].)

---

What does the market look like for rimantadine hydrochloride today?

Rimantadine has functioned as a mature, older antiviral with demand driven by seasonal influenza patterns and procurement behavior rather than by continuous innovation marketing.

Market structure

Rimantadine’s market has historically been shaped by:

• Seasonal inventory management by national and institutional buyers.
• Price and supply reliability in established manufacturing ecosystems.
• Antiviral class competition: neuraminidase inhibitors and other antiviral classes influence formulary inclusion year-to-year.
• Resistance and guideline updates that shift clinician preference when adamantane susceptibility declines.

Commercial demand drivers

Key drivers that determine whether rimantadine moves volume in a given season:

• Influenza A strain susceptibility to adamantanes in circulating viruses.
• Guideline recommendations by public health authorities and clinical societies in the buyer’s jurisdiction.
• Stocking and contracting behavior for winter season readiness.

Competitive set (functional substitutes)

Rimantadine competes with influenza therapeutics that cover similar clinical endpoints but differ in resistance profiles and usage patterns:

• Neuraminidase inhibitors (e.g., oseltamivir, zanamivir).
• Other influenza antiviral classes depending on region and time period.
  (Drug class positioning and common antiviral landscape are described in standard references used for clinical and regulatory context.) [3], [4]

---

Where is rimantadine strongest, and where does demand typically erode?

Strengths

• Cost positioning in jurisdictions that maintain rimantadine stock or that procure older influenza antivirals.
• Institutional familiarity in healthcare systems with historical use.

Erosion factors

• Adamantane resistance in influenza A reduces clinical utility in seasons with high resistance rates.
• Guideline drift to newer agents when susceptibility is low or when competing antivirals provide broader or more reliable activity.

This pattern is consistent with how older influenza antivirals have performed across time as resistance biology and standards of care evolved. (Resistance and class context are described in mainstream drug and influenza therapeutic references.) [3], [4]

---

What is the projection for rimantadine hydrochloride market value and volume over the next 3 to 5 years?

A full quantitative forecast (TAM/SAM/SOM in $) requires current unit data, country coverage, procurement contracts, and pricing series that are not contained in the provided source set. Under the available evidence base here, only a directional projection can be grounded in high-confidence commercial logic:

Directional projection (2025-2029):

• Baseline: modest, seasonally variable demand rather than sustained growth.
• Upper-bound scenario: stabilization where procurement continues and circulating influenza A remains partially susceptible to adamantanes in key geographies.
• Downside scenario: continued decline where resistance and guideline exclusion tighten further.

Three-scenario view (qualitative, decision-grade)

Scenario	2025-2029 demand trajectory	Primary driver
Stabilize	Flat to low growth	Continued formulary inclusion and manageable resistance
Downshift	Moderate decline	Resistance prevalence and guideline changes
Erosion	Sharp decline	Persistent low susceptibility and replacement by newer agents

This projection aligns with rimantadine’s historical role as a mature, class-limited antiviral with demand tied to seasonal influenza and resistance dynamics rather than to incremental innovation. [3], [4]

---

What commercialization options exist if you plan R&D or licensing around rimantadine?

Given rimantadine’s established identity and mature category, the practical path is to focus on execution elements that can win procurement decisions even without a modern registrational Phase 3 “breakthrough” profile.

Option set

1. Product lifecycle stewardship: improve manufacturability, stability, and supply continuity to secure seasonal procurement.
2. Evidence bundling: align labeling language and clinical messaging with contemporary guideline language for influenza A use cases.
3. Formulation strategy: target bioavailability consistency and patient adherence for institutional and ambulatory settings.

These options map to how mature antivirals remain commercially relevant when resistance and guidelines determine prescribing behavior more than trial innovation does. (General drug identity and class context are in cited references.) [1]-[4]

---

Key takeaways

• Rimantadine hydrochloride is a mature influenza A antiviral whose clinical activity is anchored in historical evidence, with limited visible modern late-stage registrational momentum in public trial signals.
• Market demand remains seasonally driven and is highly sensitive to influenza A adamantane resistance and to guideline/formulary inclusion by region.
• Near-term market outlook (2025-2029) is best modeled as stable-to-declining directional demand, with outcomes determined by resistance prevalence and replacement by other antiviral classes.

---

FAQs

1) Is rimantadine still clinically used for influenza A?

Yes. Rimantadine remains an influenza A antiviral in established drug references and monographs, but its clinical use is constrained by adamantane resistance patterns and guideline recommendations. [1]-[4]

2) Why does demand for rimantadine typically not grow like newer antivirals?

Because rimantadine is a mature option whose effectiveness depends on circulating virus susceptibility to adamantanes, and formularies shift when resistance is high or when guidelines favor other classes. [3], [4]

3) What determines whether rimantadine sells in a given influenza season?

Procurement and prescribing hinge on resistance prevalence in influenza A and on regional guideline/formulary inclusion decisions. [3], [4]

4) If a company wants to invest, what is the most realistic commercialization path?

Lifecycle stewardship, formulation and supply reliability, and evidence bundling aligned to contemporary guideline language are the most realistic routes for a mature antiviral category. [1]-[4]

5) Does rimantadine have a large current pipeline for new indications?

Public evidence in mainstream references treats rimantadine as an established antiviral rather than a continuously expanding modern development program; investment focus typically shifts to product/region execution instead of major new Phase 3 registrational trials. [3], [4]

---

References

[1] DailyMed. Rimantadine Hydrochloride (drug label information). U.S. National Library of Medicine.
[2] Drugs.com. Rimantadine (drug information monograph).
[3] GoodRx. Rimantadine (clinical and class overview).
[4] MedlinePlus. Rimantadine (drug information).